Landry R, Embers M
NeuroSci. 2024; 4(3):211-234.
PMID: 39483197
PMC: 11523707.
DOI: 10.3390/neurosci4030019.
Stuart C, Varatharaj A, Zou Y, Darekar A, Domjan J, Wheeler-Kingshott C
Brain Commun. 2024; 6(3):fcae143.
PMID: 38712323
PMC: 11073756.
DOI: 10.1093/braincomms/fcae143.
Darvishi S, Donnachie E, Gasperi C, Hapfelmeier A, Hemmer B
Mult Scler. 2023; 29(14):1831-1840.
PMID: 37830337
PMC: 10687801.
DOI: 10.1177/13524585231199084.
Ghasemi M, Farazandeh D, Amini B, Sedaghat M, Najafi A, Kakhki S
Mult Scler J Exp Transl Clin. 2023; 9(3):20552173231196992.
PMID: 37767104
PMC: 10521289.
DOI: 10.1177/20552173231196992.
Reder A
J Clin Invest. 2023; 133(9).
PMID: 37115699
PMC: 10145922.
DOI: 10.1172/JCI169643.
Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease.
Corbali O, Chitnis T
Front Neurol. 2023; 14:1137998.
PMID: 36925938
PMC: 10011114.
DOI: 10.3389/fneur.2023.1137998.
COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.
Rahmani M, Naser Moghadasi A, Shahi S, Eskandarieh S, Azizi H, Hasanzadeh A
Med Clin (Engl Ed). 2023; 160(5):187-192.
PMID: 36883067
PMC: 9983351.
DOI: 10.1016/j.medcle.2022.06.021.
Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study.
Miele G, Cepparulo S, Abbadessa G, Lavorgna L, Sparaco M, Simeon V
J Clin Med. 2023; 12(3).
PMID: 36769670
PMC: 9918238.
DOI: 10.3390/jcm12031023.
The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study.
Maniscalco G, Scavone C, Mascolo A, Manzo V, Prestipino E, Guglielmi G
J Clin Med. 2022; 11(22).
PMID: 36431332
PMC: 9692274.
DOI: 10.3390/jcm11226855.
COVID-19 and the risk of CNS demyelinating diseases: A systematic review.
Lotan I, Nishiyama S, Manzano G, Lydston M, Levy M
Front Neurol. 2022; 13:970383.
PMID: 36203986
PMC: 9530047.
DOI: 10.3389/fneur.2022.970383.
COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.
Rahmani M, Naser Moghadasi A, Shahi S, Eskandarieh S, Azizi H, Hasanzadeh A
Med Clin (Barc). 2022; 160(5):187-192.
PMID: 36089420
PMC: 9364744.
DOI: 10.1016/j.medcli.2022.06.020.
Multiple Sclerosis and Autoimmunity: A Veiled Relationship.
Barkhane Z, Elmadi J, Kumar L, Pugalenthi L, Ahmad M, Reddy S
Cureus. 2022; 14(4):e24294.
PMID: 35607574
PMC: 9123335.
DOI: 10.7759/cureus.24294.
Human herpesvirus 6 infection as a trigger of multiple sclerosis: an update of recent literature.
Voumvourakis K, Fragkou P, Kitsos D, Foska K, Chondrogianni M, Tsiodras S
BMC Neurol. 2022; 22(1):57.
PMID: 35168545
PMC: 8845292.
DOI: 10.1186/s12883-022-02568-7.
An integrated perspective on transmutation of acute inflammation into chronic and the role of the microbiome.
Vithoulkas G
J Med Life. 2022; 14(6):740-747.
PMID: 35126742
PMC: 8811668.
DOI: 10.25122/jml-2021-0375.
Smouldering multiple sclerosis: the 'real MS'.
Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobaeus E, Jensen M
Ther Adv Neurol Disord. 2022; 15:17562864211066751.
PMID: 35096143
PMC: 8793117.
DOI: 10.1177/17562864211066751.
Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19.
Shin R, Repovic P, Berger J
Neurol Ther. 2022; 11(2):515-524.
PMID: 35066816
PMC: 8784023.
DOI: 10.1007/s40120-021-00321-9.
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China.
Zhang Y, Yin H, Xu Y, Xu T, Peng B, Cui L
Front Neurol. 2021; 12:682729.
PMID: 34122322
PMC: 8193356.
DOI: 10.3389/fneur.2021.682729.
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.
Garjani A, Middleton R, Hunter R, Tuite-Dalton K, Coles A, Dobson R
Mult Scler Relat Disord. 2021; 52:102939.
PMID: 34010764
PMC: 9585399.
DOI: 10.1016/j.msard.2021.102939.
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
Barzegar M, Vaheb S, Mirmosayyeb O, Afshari-Safavi A, Nehzat N, Shaygannejad V
Mult Scler Relat Disord. 2021; 52:102947.
PMID: 33979771
PMC: 8036166.
DOI: 10.1016/j.msard.2021.102947.
Review of the COVID-19 Risk in Multiple Sclerosis.
Chaudhry F, Jageka C, Levy P, Cerghet M, Lisak R
J Cell Immunol. 2021; 3(2):68-77.
PMID: 33959727
PMC: 8098748.
DOI: 10.33696/immunology.3.080.